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Glutaredoxins are thiol oxidoreductases that regulate
protein redox state. In Saccharomyces cerevisiae, Grx1
and Grx2 are cytosolic dithiol glutaredoxins, whereas
Grx3, Grx4, and Grx5 are monothiol glutaredoxins. Grx5
locates at the mitochondrial matrix and is needed for
iron/sulfur cluster biogenesis. Its absence causes pheno-
types such as inactivation of iron/sulfur enzymes and
sensitivity to oxidative stress. Whereas Grx5 contains a
single glutaredoxin domain, in Grx3 and Grx4 a thio-
redoxin-like domain is fused to the glutaredoxin do-
main. Here we have shown that Grx3 locates at the nu-
cleus and that the thioredoxin-like domain is required
for such location. We have addressed the functional di-
vergence among glutaredoxins by targeting Grx2/3/4
molecules to the mitochondrial matrix using the Grx5
targeting sequence. The mitochondrial forms of Grx3
and Grx4 partially rescue the defects of a grx5 null mu-
tant. On the contrary, mitochondrially targeted Grx2
does not suppress the mutant phenotype. Both the thi-
oredoxin-like and glutaredoxin domains are needed for
the mitochondrial activity of Grx3, although none of
the cysteine residues at the thioredoxin-like domain is
required for rescue of the grx5 phenotypes. We have
concluded that dithiol glutaredoxins are functionally
divergent from monothiol ones, but the latter can inter-
change their biological activities when compartment
barriers are surpassed.
Glutaredoxins (Grx)1 are small (10 kDa) thiol disulfide
oxidoreductases that catalyze glutathione (GSH)-disulfide re-
dox reactions (1, 2). They reduce protein disulfides through a
dithiol mechanism that involves two cysteine residues in the
active site of the glutaredoxin molecule, or they deglutathion-
ylate GSH-protein mixed disulfides through a monothiol mech-
anism of action involving a single cysteine at the active site (2).
In contrast to glutaredoxins, thioredoxins employ NADPH di-
rectly as hydrogen donor. Besides glutaredoxins and GSH, the
glutaredoxin system also includes glutaredoxin reductases that
regenerate GSH from glutathione disulfide. Glutaredoxins
have a number of biological roles. These include activation of
ribonucleotide reductase (1, 3) and 3-phosphoadenylylsulfate
reductase (4), reduction of ascorbate (5), GSH-mediated reduc-
tion of dihydrolipoamide (6), regulation of the DNA binding
activity of nuclear factors (7), neuronal protection against do-
pamine-induced apoptosis (8) and excitotoxic mitochondrial
damage (9), and regulation of signal cascades that protect
against oxidative stress (10, 11). Glutaredoxins play an impor-
tant role in protecting against protein oxidative damage by
regulating the glutathionylated state of essential sulfhydryl
groups (12). To carry out the above functions, glutaredoxins are
present in various different cell compartments. In human cells,
Grx1 glutaredoxin is cytosolic (13), whereas a second gluta-
redoxin (Grx2) has two isoforms that are, respectively, located
at the nucleus and the mitochondria (14, 15). In plants, gluta-
redoxins have also been described at the cytosol and mitochon-
dria (16). The existence of cross-talk between the glutaredoxin
and thioredoxin systems is illustrated by the fact that human
Grx2 is able to deglutathionylate GSH-protein mixed disulfides
through thioredoxin reductase as an alternative to GSH (17).
The thioredoxin and glutaredoxin systems are also present
in yeasts (18–20). Saccharomyces cerevisiae contains both a
cytosolic and a mitochondrial thioredoxin system (21, 22)
whose functions may overlap with those of the glutaredoxin
system (23). S. cerevisiae contains two glutaredoxins (Grx1 and
Grx2) with conserved CPYC motifs in their active sites (24).
Both are cytosolic, though a minor fraction of Grx2 molecules is
located at the mitochondria (25). A single glutathione reduc-
tase (Grr1) shares a cytosolic and mitochondrial location (26).
In addition to the dithiol glutaredoxins, S. cerevisiae cells con-
tain three monothiol glutaredoxins (Grx3, Grx4, and Grx5)
with the motif CGFS in their active sites (27, 28). Grx5 is
located at the mitochondrial matrix and participates in the
biogenesis of iron/sulfur (Fe/S) clusters (29, 30). The absence of
Grx5 causes the inactivation of enzymes containing Fe/S clus-
ters, intracellular iron accumulation, hypersensitivity to exter-
nal oxidants, high levels of protein oxidation, auxotrophy for a
number of amino acids, and low growth rates in rich medium
(27, 29). A number of proteins also become hyperglutathionyl-
ated in null grx5 mutants (31). All of these phenotypes are
probably a consequence of disruption of the Grx5 function in
the biogenesis of Fe/S clusters because most of the alterations
are shared by other mutants affected in the biogenesis of the
clusters (32, 33). Grx3 and Grx4 molecules are larger than
Grx5 because they contain a thioredoxin-like domain that is
N-terminal located relative to the glutaredoxin domain, with a
linking region between the two domains (28, 34).
Yeast monothiol glutaredoxins are members of a large group
of proteins present in organisms ranging from bacteria to
higher eukaryotes (28, 35). The human member is the PICOT
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protein, a negative regulator of protein kinase  in the pathway
that controls c-Jun N-terminal kinase (36). This translocates
from the cytosol to the nucleus in response to oxidative stress
(37). The mouse PICOT homologue is differentially expressed
at stages of mouse embryogenesis concomitant with neural
tube closure (38).
Some functional interactions may exist between monothiol and
dithiol glutaredoxins in S. cerevisiae. However, they do not fully
substitute each other because the overexpression of Grx3 or Grx4
does not rescue the above defects of grx5 cells (29). It has recently
been shown that Grx4 is located at the nucleus and that it
interacts with the Bud32 protein kinase (39). In the current work
we have demonstrated that Grx3 is also located at the nucleus
and that its thioredoxin-like domain is required for nuclear tar-
geting. We have also shown that when either Grx3 or Grx4 are
targeted to the mitochondria they can substitute for Grx5 func-
tion, unlike dithiol glutaredoxins. Therefore, differential com-
partmentalization determines separate biological functions for
the members of the monothiol glutaredoxin family.
EXPERIMENTAL PROCEDURES
Yeast Strains and Plasmids—The yeast strains employed in this
work are described in Table I. Plasmid pMM221 was based on the LEU2
integrative vector YIplac128 (40), with the doxycycline-controlled tTA
transactivator and tetO2 promoter regions from pCM188 (41), the mi-
tochondrial targeting sequence of GRX5 from pCM318 (29), and the
3HA/His6 tag from pCM265 (42), plus a polylinker created with ade-
quate complementary oligonucleotides. Plasmid pMM225 contains the
GRX2 coding sequence from the nucleotide at position 103 to the last
coding nucleotide, which is in-frame with the 3HA/His6 tag. It was
cloned between the NotI and PstI sites of the vector pMM221. Similarly,
plasmids pMM227 and pMM229, respectively, contain the GRX3 and
GRX4 coding sequences from the second to the last coding codon, cloned
between the NotI and PstI sites of pMM221. Plasmids pMM338,
pMM340, and pMM342 derive from pMM221 by, respectively, cloning
the sequences of GRX3 coding from amino acid 2 to 133 (including the
Trx domain), 2 to 198 (Trx domain plus linker), or 199 to 285 (Grx
domain) between the NotI and PstI sites of the vector. pMM344,
pMM349, pMM387, and pMM451 are pMM227 derivatives with the
following respective point mutations in the Grx3 sequence: C72S,
C211S, C2S, and C18A. Plasmid pMM453 also derives from pMM227
and contains the three point mutations C2S, C18A, C72S in the coding
sequence for Grx3. GFP fusions to different regions of Grx3 were con-
structed under the control of the MET25 promoter in pUG35 (from
W. H. Hegemann, Institute of Microbiology, Duesseldorf, Germany),
using the EcoRI and HindIII vector sites. pMM423 and pMM421, re-
spectively, contain the GRX3 coding sequences from amino acid 1 to 133
and 199 to 285, in-frame with the GFP sequence at the C terminus.
Plasmid pMM425 is a pUG35 derivative with the whole GRX3 sequence
C-terminal tagged with GFP.
Growth Conditions—YPD medium (1% yeast extract, 2% peptone, 2%
dextrose) was usually employed. YPGly and YPGal media are similar to
YPD except that they, respectively, contain 3% glycerol and 2% galac-
tose instead of dextrose. Synthetic S.D. medium contains 0.67% yeast
nitrogen base, 2% glucose, and the auxotrophic requirements. Doxycy-
cline was added to the medium at the indicated concentrations to
modulate expression from the tetO2 promoter. Cells were exponentially
grown at 30 °C under the required conditions for at least 10 generations
before samples were taken for analysis.
Genetic Methods—Standard methods were employed for DNA ma-
nipulation, transformation, crosses between yeast strains, and tetrad
analyses. PCR-amplified S. cerevisiae genomic DNA was used for clon-
ing with appropriate oligonucleotides for amplification that created the
required restriction sites. Point mutants to yield the different amino
acid replacements were constructed by the ExSite method (43). In this
case, oligonucleotides for PCR amplifications were designed in such a
way that a restriction site not altering the translation product was
introduced as a marker near the desired point mutation. Introduction of
the mutations was confirmed by DNA sequencing. Integrative plasmids
were made linear by EcoRV digestion before transformation of the wild
type cells to yield the respective derivatives.
Other Methods—Mitochondria were purified and fractionated from
cell cultures in lactate medium as described in Ref. 44. Western blot
analyses were done as in Ref. 29, with 12CA5 anti-HA monoclonal
antibody (Roche Diagnostics) at a 1:5,000 dilution and anti-lipoic acid
antibody at 1:50,000 dilution. Aconitase and malate dehydrogenase
were assayed following the methods described in Ref. 45. Extracts from
cells growing exponentially in YPGal medium were prepared in 0.1 M
Tris buffer, pH 8.0, plus protease inhibitors (2 mM phenylmethylsulfo-
nyl fluoride, 0.2 mM tolylsulfonyl phenylalanyl chloromethyl ketone, 2
M pepstatin A, final concentrations), using glass beads to break the
cells. Microscopic localization of GFP-labeled proteins in living cells was
done by standard techniques (46).
RESULTS
The Thioredoxin-like Domain of Grx3 Is Required for Target-
ing the Protein to the Nucleus—The three monothiol gluta-
redoxins of S. cerevisiae share a Grx domain that displays
partial homology with dithiol glutaredoxins and contains the
single cysteine active site (27, 28) (Fig. 1A). This conserved
domain has also been termed PICOT after its presence in the
human PICOT protein (34). In addition, Grx3 and Grx4 contain
TABLE I
Strains employed in this work
Strain Relevant phenotype Comments
W303–1A MATa ura3–1 ade2–1 leu2–3,112 trp1–1 his3–11,15 Wild type
W303–1B As W303–1A but MATa Wild type
MML100 MATa grx5::kanMX4 Ref. 29
MML240 MATa grx5::kanMX4 pMM54(GRX5–3HA)::LEU2 Ref. 29
MML241 MAT grx5::kanMX4 As MML100, but derived from W301–1B
MML443 MATa pMM227(GRX3–3HA)::LEU2 Integration of linear pMM227 in W303–1A
MML446 MATa pMM229(GRX4–3HA)::LEU2 Integration of linear pMM229 in W303–1A
MML458 MATa pMM225(GRX2–3HA)::LEU2 Integration of linear pMM225 in W303–1B
MML454 MATa grx5::kanMX4 pMM227(GRX3–3HA)::LEU2 Spore from a cross MML241  MML443
MML456 MATa grx5::kanMX4 pMM229(GRX4–3HA)::LEU2 Spore from a cross MML241  MML446
MML465 MATa grx5::kanMX4 pMM225(GRX2–3HA)::LEU2 Spore from a cross MML100  MML458
MML488 MATa pMM338::LEU2 Integration of linear pMM338 in W303–1B
MML490 MATa pMM340::LEU2 Integration of linear pMM340 in W303–1B
MML492 MATa pMM342::LEU2 Integration of linear pMM342 in W303–1B
MML500 MATa grx5::kanMX4 pMM338::LEU2 Spore from a cross MML100  MML488
MML502 MATa grx5::kanMX4 pMM340::LEU2 Spore from a cross MML100  MML490
MML504 MATa grx5::kanMX4 pMM342::LEU2 Spore from a cross MML100  MML492
MML507 MATa pMM344(GRX3-C72S-3HA)::LEU2 Integration of linear pMM344 in W303–1B
MML509 MATa pMM349(GRX3-C211S-3HA)::LEU2 Integration of linear pMM349 in W303–1B
MML514 MATa grx5::kanMX4 a pMM349(GRX3-C211 S-3HA)::LEU2 Spore from a cross MML100  MML509
MML516 MATa grx5::kanMX4 a pMM344(GRX3-C72S-3HA)::LEU2 Spore from a cross MML100  MML507
MML563 MATa pMM387 (GRX3-C2S-3HA)::LEU2 Integration of linear pMM387 in W303–1B
MML566 MATa grx5::kanMX4 a pMM387(GRX3-C2S-3HA)::LEU2 Spore from a cross MML100  MML563
MML607 MATa pMM221::LEU2 Integration of linear pMM221 in W303–1A
MML614B MATa grx5::kanMX4 pMM221::LEU2 Spore from a cross MML241  MML607
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an N-terminal extension that is highly homologous to thiore-
doxin sequences (Trx domain in Fig. 1A). This domain is not
present in Grx5, which instead contains a mitochondrial tar-
geting sequence (29). The Trx domain contains a WAD/EPCK
sequence that is reminiscent of the authentic thioredoxin active
site motif WCGPCK (47). The Trx domain is conserved in many
members of the Grx3/Grx4 protein family in other eukaryotic
organisms (28, 35). A non-conserved linker region is present
between the Trx and Grx domains (Fig. 1A). It has recently
been shown that Grx4 is located at the nucleus (39). Using a C
terminus GFP-tagged construction under the control of the
MET25 promoter, we have observed that Grx3 is also targeted
to the nucleus in conditions of maximum expression from the
promoter (Fig. 1B). When the expression level of the Grx3GFP
fusion protein was reduced by adding intermediate methionine
concentrations (up to 25 M) to the growth medium, Grx3 was
still concentrated at the nucleus (not shown), discarding any
possible abnormal location caused by overexpression. We con-
cluded that Grx3 and Grx4 are both nuclear glutaredoxins,
which suggests that their functions could be redundant.
To determine the region of Grx3 responsible for its nuclear
localization, the Trx and Grx domains were separately tagged
with GFP in the same MET25-based vector as above. Cells
expressing the TrxGFP construction showed a nuclear fluores-
cence pattern, whereas those with the GrxGFP construction
showed diffuse fluorescence (Fig. 1B). This indicates that the
Trx domain (but not the Grx domain) contains a nuclear loca-
tion signal for Grx3 and is able to be directed to the nucleus on
its own. Analysis of the Trx region amino acid sequence did not
reveal either a simple or bipartite canonical nuclear localiza-
tion signal (48). We addressed the possibility of Grx3 location
being regulated by external stresses in a similar way to the
external conditions-controlled nuclear location of several tran-
scription factors that mediate stress responses (Msn2/4, Yap1,
Aft1) (19, 49, 50). However, neither heat shock, hydrogen per-
oxide-mediated oxidative stress, nor entry into the post-diauxic
stage of the growth curve affected the nuclear location of Grx3
(Fig. 1C). We have therefore concluded that Grx3 has a consti-
tutive nuclear location.
Grx3 and Grx4, but Not Grx2, Rescue the Defects of Cells
Lacking Grx5—The fact that overexpression of native Grx3 or
Grx4 glutaredoxins does not rescue the defects of a null grx5
mutant (29) could be a consequence of their different cellular
compartmentalizations with respect to Grx5. We wondered
what would happen in a situation in which Grx3 or Grx4 was
targeted to the mitochondria in the absence of Grx5. We were
also interested in determining the ability of a mitochondrially
targeted form of the dithiol glutaredoxin Grx2 to substitute for
Grx5 function when overexpressed. Grx2 is mostly located at
the cytosol, although a minor fraction could be mitochondrial
(25). With this objective, we constructed a vector (Fig. 2A) in
which the desired gene was fused to the coding sequence of the
mitochondria targeting signal of the Grx5 protein. In this vec-
tor (pMM221), expression of the HA-tagged chimeric protein
was controlled by a tetO2 promoter that also made it possible to
modulate its expression according to doxycycline concentration.
pMM221 was employed to clone the GRX2, GRX3, and GRX4
sequences. In the case of GRX2, the sequence cloned began at
the codon coding for methionine at position 35 in the open
reading frame. In other words, the resulting construct con-
sisted of the Grx5 mitochondrial targeting sequence fused to
the Grx2 form that predominantly compartmentalizes at the
cytosol (25). In the case of the two monothiol glutaredoxin
genes, the initial ATG codons in the respective open reading
frames were omitted in the pMM221-based constructions.
Yeast cells transformed with either of the respective con-
structions in the pMM221 vector were able to direct Grx2,
Grx3, or Grx4 to the mitochondria. When identical amounts of
total mitochondrial protein were analyzed from cultures grown
in the absence of doxycycline, the levels of the HA-tagged forms
FIG. 1. Nuclear localization of Grx3.
A, domains of the monothiol glutaredox-
ins Grx3, Grx4, and Grx5. The thiore-
doxin-like (Trx) and glutaredoxin (Grx)
domains are indicated with the positions
of the initial and final amino acids at each
domain (see Ref. 34 for more details). The
conserved sequences at the Trx domain of
Grx3 and Grx4 that are reminiscent of the
thioredoxin active site are also shown.
The position of the cysteine at the active
site of the Grx domain is indicated. The
black box corresponds to the mitochon-
drial targeting sequence of Grx5. B, fluo-
rescence micrographs of exponentially
growing cells in S.D. medium without me-
thionine at 30 °C expressing the whole
Grx3 sequence (pMM425) or the Trx
(pMM423) or Grx (pMM421) domains of
Grx3, tagged at the C terminus with GFP.
Cells were also 4,6-diamidino-2-phe-
nylindole (DAPI)-stained; images are
shown in parallel. C, exponentially grow-
ing cells in S.D. medium at 30 °C express-
ing Grx3GFP (pMM425) were subjected
to heat shock (30 min at 38 °C), hydrogen
peroxide treatment (0.5 mM, 1 h), or cul-
tured until early stationary phase (72 h at
30 °C). GFP fluorescent and DAPI-
stained cells are shown.
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of the above glutaredoxins were considerably higher than the
level of endogenous Grx5-HA (Fig. 2B). This confirmed that
tetO2 is a strong promoter (41) and is responsible for protein
overexpression even when it is present in a single copy inte-
grative plasmid such as pMM221. Importantly, all the mito-
chondrial glutaredoxin molecules were compartmentalized at
the matrix, as occurs with Grx5 (Fig. 2B and Ref. 29). This
compartmentalization pattern was the same as that of the
matrix lipoic-containing protein -ketoglutarate dehydrogen-
ase. The respective mobilities of the Grx-HA bands in the
mitochondrial fraction corresponded to the expected sizes of the
mature proteins once the Grx5 targeting sequence had been
processed. In some cases, a lower mobility band was present in
minor amounts in the total extract fraction (Fig. 2B); this
probably corresponded to the non-processed precursor form of
the mitochondrial molecules.
Mitochondrially expressed Grx2 was not able to rescue the
growth defects of a mutant lacking Grx5 (Fig. 3, A and B). In
contrast, these defects were rescued when either Grx3 or Grx4
was targeted to the mitochondrial matrix. In fact, in rich (YP-
Gal) media, these cells exhibited growth rates similar to wild
type cells (Fig. 3A) and were able to grow in minimal S.D.
medium or in respiratory conditions in which glycerol was the
only carbon source (Fig. 3B).
To quantify the ability of the mitochondrial Grx3 or Grx4
forms to substitute for the biological function of Grx5, we de-
termined aconitase activity (relative to malate dehydrogenase)
in the respective strains. Aconitase is a mitochondrial enzyme
that contains Fe/S clusters and whose activity is depleted in
null grx5 mutants (29), whereas malate dehydrogenase, which
is also mitochondrial, lacks such clusters. Because the activity
of mitochondrial enzymes is significantly decreased in glucose
media, experiments were done in a rich medium with galactose
as the carbon source. These are conditions compatible with
growth competence of all the strains employed in this study.
Importantly, absolute levels of malate dehydrogenase did not
significantly vary from one strain to another (data not shown),
which indicated the absence of any nonspecific mitochondrial
dysfunction. In accordance with the previously described
growth phenotypes, overexpressed mitochondrial Grx2 did not
rescue the aconitase activity defect in the grx5 background
(Fig. 4). However, overexpression of Grx3 or Grx4 did rescue
this defect. To know whether aconitase activity was also re-
stored when either Grx3 or Grx4 was expressed at levels equiv-
alent to those of Grx5, we modulated the expression of the
GRX3-HA or GRX4-HA constructs from the tetO2 promoter
with intermediate concentrations of doxycycline. When ex-
pressed levels of Grx3 or Grx4 were similar to those of endog-
FIG. 2. Plasmid pMM221 compartmentalizes proteins in the mitochondrial matrix through the Grx5 mitochondrial targeting
sequence. A, the plasmid is based on pCM318 (29), which contains the GRX5–3HA-His6 region under the tTA-mediated control of the tetO2
promoter. From this plasmid, the GRX5 open reading frame (except the sequence coding for the initial 29 amino acids corresponding to the
mitochondrial targeting sequence) was replaced by a synthetic multiple cloning site (MCS) generated with complementary oligonucleotides. The
whole expression cassette (EcoRI-HindIII fragment) was then moved to the LEU2 integrative vector YIplac128. For more details on the tTA-ADH1
terminator tetO2 and 3HA-His6 regions, see Refs. 41 and 42, respectively. B, derivatives of pMM221 are able to compartmentalize Grx2 (pMM225,
integrated in strain MML458), Grx3 (pMM227, strain MML443), and Grx4 (pMM229, strain MML446) at the mitochondrial matrix. Cultures of
the respective strains were exponentially grown in lactate medium at 30 °C to an A (600 nm) of about 0.6 before mitochondrial isolation and
subfractionation. Strain MML240 expressing a Grx5–3HA protein under its own promoter was employed as a control. TE, total cell extract; MT,
mitochondrial fraction; IMS, intermembrane space; MX, matrix. Ten micrograms of protein were loaded in the TE lanes, whereas 1 g was loaded
in the other lanes. Anti-HA antibodies were used in the Western blot analyses to detect the HA-tagged proteins in the respective fractions, whereas
anti-lipoic acid antibodies were used to detect the matrix marker -ketoglutarate dehydrogenase (-KGDH). Coomassie Blue staining confirmed
that submitochondrial fractions were not significantly cross-contaminated (not shown).
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enous Grx5 (Fig. 4, upper panels), aconitase activity was only
partially restored in the grx5 cells. High concentration of
doxycycline (4 g/ml) almost totally switched off expression
from the tet promoter; in these conditions, aconitase activity
was comparable with that in grx5 cells (Fig. 4). The two
monothiol glutaredoxins, Grx3 and Grx4, were therefore only
able to completely substitute the mitochondrial Grx5 function
when they were overexpressed.
FIG. 3. Rescue of thegrx5mutant growth defects bymitochondrial forms of glutaredoxins.A, doubling times in min (bars, means of three
experiments) were calculated from exponential cultures in liquid YPD medium at 30 °C. The strains employed carry a chromosomal null grx5 allele and
express the following mitochondrial glutaredoxin forms: MML240 (Grx5, endogenous promoter), MML100 (No Grx), MML465 (Grx2, pMM221-based),
MML454 (Grx3, pMM221-based), MML456 (Grx4, pMM221-based). B, growth on S.D. or YPGly plates after 3 days at 30 °C of the following
chromosomal grx5 strains expressing the indicated mitochondrial glutaredoxins: MML240 (Grx5), MML614B (No Grx), MML465 (Grx2), MML454
(Grx3), MML456 (Grx4).
FIG. 4. Ratio between aconitase and malate dehydrogenase activities in exponential cells at 30 °C in YPGal medium. Strains that
express different mitochondrial HA-tagged glutaredoxin forms were employed: W303–1A (wild type), MML240 (grx5/GRX5, endogenous GRX5
promoter), MML100 (grx5), MML465 (grx5/GRX2mit, pMM221-based), MML454 (grx5/GRX3mit, pMM221-based), MML456 (grx5/GRX4mit,
pMM221-based). Doxycycline was employed at the indicated concentrations in the growth medium to modulate expression from the tetO2 promoter.
Values are normalized with respect to the ratio in the wild type strain (unit value). Upper panels show the Western blot analyses of HA-tagged
glutaredoxins in total cell extracts from the following strains: MML240 (Grx5), MML465 (Grx2mit), MML454 (Grx3mit), and MML456 (Grx4mit).
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The Mitochondrially Located Trx or Grx Domains of Grx3 Do
Not Rescue the grx5 Defects When Expressed Separately—The
partial ability of Grx3 or Grx4 to substitute for the Grx5 bio-
logical function at the mitochondria could be caused by impair-
ment of the function of the Grx domain because of the bulky Trx
domain. Alternatively, this could be the result of partial enzy-
matic activity of the Grx domain of Grx3 or Grx4 in contrast
with the mature Grx5 protein. To distinguish between the two
possibilities, we separately targeted the Trx, Trx plus linker, or
Grx domains of Grx3 to the mitochondria using the pMM221
vector. The three domains were detected as overexpressed pro-
teins (Fig. 5B) and became localized at the matrix (data not
shown). However, neither the Trx nor the Grx regions alone nor
the Trx plus linker region could complement the phenotypes
caused by the absence of Grx5. Growth in minimal S.D. me-
dium or in glycerol respiratory conditions (Fig. 5A) and aconi-
tase/malate dehydrogenase activities were defective in grx5
cells expressing the truncated versions of Grx3 (Fig. 5B). This
indicated that the Grx domain of Grx3 is not functionally
equivalent to Grx5 and that the partial biological activity of
Grx3 compared with Grx5 is not exclusively because of inter-
ference between the Trx and Grx domains.
Only the Cysteine Residue at the Glutaredoxin Domain Is
Required for the Biological Activity of Grx3—Grx3 contains two
cysteine residues at positions 72 (Trx domain) and 211 (Grx
domain) that are conserved at equivalent positions in Grx4 and
in homologues present in other organisms (28, 34). Cys-72 is in
the context of the partially conserved thioredoxin active site
(Fig. 1A). The observation that both the Trx and Grx domains
are required if Grx3 is to replace the biological activity of Grx5
at the mitochondria could be explained by the need for both
Cys-72 and Cys-211. If this were the case, Grx3 would, in fact,
act through a dithiol mechanism of action. To test this hypoth-
esis, we separately mutated the two cysteine residues and
targeted the respective Grx3 derivatives to the mitochondria of
grx5 cells. Only the C211S substitution eliminated the Grx3
activity, as well as aconitase/malate dehydrogenase activities,
when we measured growth in minimal medium or under res-
piratory conditions (Fig. 6, A and B). Cellular fractionation
analyses showed that this mutant form still localizes at the
mitochondrial matrix (data not shown). This indicates that the
conserved cysteine at the Trx domain does not play a signifi-
cant role at the mitochondria. Two other cysteine residues that
are present in the context of the Trx domain of Grx3 at posi-
tions 2 and 18 are not conserved in Grx4 or in other members
of the same family. We decided to test whether either of these
two residues could have an active role in Grx3, at least in the
absence of Cys-72. We therefore constructed single point
mutants in both of these cysteines, along with a triple
C2S,C18A,C72S mutant, and expressed them as mitochondrial
Grx3 forms in grx5 cells. The single C2S or C18A mutant
Grx3 forms as well as the triple mutant derivative behave like
the wild type Grx3 form once internalized into the mitochon-
dria of grx5 cells when the aconitase/malate dehydrogenase
activity ratio (Fig. 6B) or the ability for growth in minimal or
glycerol medium (not shown) were determined. We concluded
that cysteine at position 211 is required for the biological ac-
tivity of Grx3 at the mitochondria and that the cysteine resi-
dues at the Trx region are not required for the redox function of
the Grx moiety.
DISCUSSION
Grx3, Grx4, and Grx5 are monothiol glutaredoxins that lo-
calize at different cellular compartments in S. cerevisiae cells.
We had previously shown that Grx5 is located at the mitochon-
drial matrix (29); the present study has demonstrated the
nuclear location of Grx3, which is similar to that of Grx4 (39).
This nuclear location is not affected by a number of stresses.
These glutaredoxins are an example of a protein family whose
members are differentially compartmentalized, therefore
pointing to divergent biological functions. Protein families may
emerge from duplication events affecting genome regions of
variable lengths. They are a source of functional diversification
and allow organisms to adapt to their environments with
greater efficiency (51). S. cerevisiae contains a large number of
families, ranging from 2 to more than 100 gene members (52).
An ancient poliploidization event, which could have occurred
about 200 million years ago, may have been the origin of such
a large number of gene families (53), although later, shorter,
independent duplications could have contributed to the diver-
sity of such families and also to the number and wide range of
family members (54). Differential compartmentalization of the
respective protein products of a gene family may play an im-
FIG. 5. Rescue of the growth defects of a grx5 mutant by
mitochondrial truncated derivatives of Grx3. A, growth on S.D. or
YPGly plates (3 days at 30 °C) of the following strains carrying the
chromosomal grx5 allele and expressing the indicated mitochondrial
glutaredoxin forms: MML240 (Grx5, endogenous promoter), MML614B
(No Grx), MML500 (Trx domain of Grx3, pMM221-based), MML502
(Trx plus linker domain of Grx3), and MML504 (Grx domain of Grx3). B,
ration between aconitase and malate dehydrogenase activities in expo-
nential cells at 30 °C in YPGal medium expressing GRX5 or truncated
derivatives of GRX3 coding for the respective mitochondrial forms:
W303–1A (wild type), MML240 (grx5/GRX5), MML100 (grx5),
MML502 (grx5-/GRX3(Trx-linker)mit), MML504 (grx5/GRX3(Grx)mit),
and MML500 (grx5/GRX3(Trx)mit). Values are normalized with respect
to the ratio in the wild type strain (unit value). The upper panel shows the
Western blot analysis of the HA-tagged forms in the respective strains:
MML240 (Grx5), MML502 (Trx-linkermit), MML504 (Grxmit), and
MML500 (Trxmit).
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portant role in biological adaptation to changes in external
conditions. Among proteins implicated in defense against oxi-
dative stress in S. cerevisiae, there are several examples of
molecules with the same enzyme activity having different lo-
cations (see Ref. 19 for a review). However, the picture may be
more complicated than this. For instance, Sod1 Cu,Zn-depend-
ent superoxide dismutase is located at both the cytosol (major
form) and mitochondria (55). Alternative translation from two
different start codons of GLR1 mRNA generates mitochondrial
or cytosolic isoforms of Glr1 glutathione reductase (26). Also,
post-translational processing may lead to cytosolic and mito-
chondrial forms of the dithiol glutaredoxin Grx2 (25). There-
fore, a single gene can code for products with alternative loca-
tions due to transcriptional or post-transcriptional events.
There are significant structural differences between mem-
bers of the Grx3/Grx4/Grx5 family. The fusion of a thioredoxin-
like domain to a glutaredoxin domain may have occurred in a
eukaryotic common ancestor of S. cerevisiae and other yeasts
(34) as an important event in the functional specialization of
the Grx3/Grx4 pair (Trx-Grx structure) with respect to Grx5
(with only the glutaredoxin domain). In the present study we
have shown that the thioredoxin-like domain is essential for
the nuclear location of Grx3 (and probably also for that of Grx4,
given the similarity between the two proteins), although no
canonical nuclear localization sequences are detectable in the
Trx domains of Grx3 or Grx4. This is not the first example of a
nuclear glutaredoxin, as an isoform of human Grx2 (of the
dithiolic class) also occurs at the nucleus (14, 15). In the case of
thioredoxins, there are multiple examples of nuclear forms
that, among other functions, could be involved in regulation of
transcription factors (47). Although the possible regulatory role
of nuclear glutaredoxins has not been determined, in particular
of human Grx2, it is tempting to speculate that they also may
regulate the redox state of essential cysteine residues of nu-
clear transcription factors via reversible glutathionylation. Re-
lated to this, it has been shown that glutathionylation of a
cysteine residue from a NF-B subunit regulates the DNA
binding activity of the latter (56).
Grx3 and Grx4 glutaredoxins are an example of how fusion of
different protein domains may be a source of functional diver-
sity. In the case of enzyme activities involved in oxidative
stress responses, the existence of thiol peroxidaseglutaredoxin
fusion proteins has recently been demonstrated in a number of
different bacteria (57, 58). In these molecules, the glutaredoxin
moiety acts as a donor of reducing power for the thiol peroxi-
dase-mediated reduction of hydroperoxides. Thioredoxin do-
mains can also be part of fusion proteins, for instance fused to
nucleoside-diphosphate kinase domains (see Ref. 59 and cita-
tions therein). The hypothetical activity of the Trx moiety in
Grx3 remains, however, unclear. One of the two cysteine resi-
dues that are essential for the thiol-oxidoreductase activity of
these molecules is missing from the sequence reminiscent of
the thioredoxin active site. Here, we have also shown that none
of the cysteine residues in the Trx domain of Grx3 is required
for the activity of the molecule; this includes the above men-
tioned cysteine. In contrast, the single cysteine residue in the
Grx domain is essential. It is also important to note that Grx4
does not contain other cysteine residues apart from one in the
Grx domain active site and another in the active site-like re-
gion of the Trx domain (Fig. 1A), and yet it is still able to rescue
the grx5 phenotypes when targeted to the mitochondria. We
have therefore concluded that Grx3 (and probably Grx4 also) is
really a monothiol glutaredoxin and that although the Trx
domain is required for nuclear targeting of the molecule, it does
not actively participate in the thiol-oxidoreductase reaction.
However, the Trx domain is required for the activity of the
Grx3 molecules, at least when targeted to the mitochondria,
probably because it stabilizes the conformation of the Grx do-
main in an active state. We have made in silico models of the
Grx3 three-dimensional structure in which the Trx domain
comes into close contact with the Grx domain in a stable con-
formation (data not shown).
In a previous study (27), we showed the synthetic lethality of
the grx2 and grx5 mutations. However, Grx2 and Grx5 do
not have overlapping functions, as we have demonstrated here
that Grx2 does not substitute for the absence of Grx5 even
when it is overexpressed at the mitochondria. The synthetic
lethality between the two mutants could be because of less
direct reasons, such as the fact that yeast cells lacking Grx2
cannot cope with the general oxidation of cellular proteins that
occurs in the absence of Grx5 (27). The phenotype of a grx2
mutant discards the participation of Grx2 in the mitochondrial
synthesis of iron/sulfur clusters, even though a small amount of
this glutaredoxin compartmentalizes at the mitochondria (25).
Results from physiological studies shown here reinforce the
idea based on enzymatic analyses that dithiol and monothiol
glutaredoxins have different mechanisms of action (1, 60, 61).
FIG. 6. Rescue of the growth defects of a grx5 mutant by
mitochondrial derivatives of Grx3 carrying point mutations. A,
growth on S.D. or YPGly plates (3 days at 30 °C) of the following strains
carrying the chromosomal grx5 allele and expressing the indicated
mitochondrial glutaredoxins: MML240 (Grx5), MML614B (No Grx),
MML516 (Grx3 C72S), MML514 (Grx3 C211S). B, ratio aconitase/
malate dehydrogenase in exponential cells at 30 °C in YPGal medium,
corresponding to the following strains: W303–1A (wild type), MML240
(grx5/GRX5), MML100 (grx5), MML516 (grx5/GRX3(C72S)mit),
MML514 (grx5/GRX3(C211S)mit), MML566 (grx5/GRX3(C2S)mit),
MML642 (grx5/GRX3(C18A)mit), and MML644 (grx5/GRX3(C2S,
C18A,C72S)mit). Values are normalized with respect to the ratio in the
wild type strain (unit value).
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Dithiol glutaredoxins reduce both cysteine residues forming a
disulfide bond, whereas monothiol glutaredoxins act by deglu-
tathionylating GSH-protein mixed disulfides. At the mitochon-
drial iron-sulfur assembly complex, Grx5 seems to act in the
later steps in the biosynthetic process, probably by maintaining
the essential cysteine residues of the assembly complex in a
reduced state (30). This would involve the deglutathionylation
of mixed disulfides affecting such cysteine residues. In vitro
studies have shown that dithiol glutaredoxin mutants that lack
the most C-terminal of the cysteine residues at the active site
are still able to deglutathionylate substrates (60); however, our
results indicate that the mitochondrial function related to iron/
sulfur cluster assembly cannot be carried out by a dithiol glu-
taredoxin such as Grx2.
On the contrary, Grx3 and Grx4 are able to substitute for
Grx5 at the mitochondria. This does not mean that they nor-
mally participate in the synthesis of iron/sulfur clusters, be-
cause this process occurs exclusively at the mitochondria in
S. cerevisiae (62). However, when one of those glutaredoxins is
addressed to the mitochondria, it is then able to acquire this
new function in the iron/sulfur assembly complex although not
as efficiently as Grx5 itself. The mitochondrial forms of Grx3 or
Grx4 only totally rescue the absence of Grx5 as determined by
aconitase activity levels when they are overexpressed. Surpris-
ingly, both Trx and Grx domains are required for this function,
though only the cysteine residue of the latter domain is biolog-
ically active. The molecule probably only adopts an active con-
formation that is sufficient to carry out the function in the
iron/sulfur assembly complex when both domains are present.
This is an example of molecules sharing the same enzyme
activity that functionally diverge through acquisition of new
protein domains and separate compartmentalization. We hy-
pothesize that the function of Grx3/Grx4 at the nucleus has
evolved from an ancient glutaredoxin participating in the bio-
genesis of the iron/sulfur clusters, based on (i) the similarity
between the phylogenetic profiles of orthologs of Grx5 and
other components of the iron/sulfur assembly complex among
bacterial species and (ii) the absence of molecules with the
Trx-Grx structure among bacteria and archea (34). Following
this reasoning, we propose that bacterial monothiol glutaredox-
ins are also involved in the biogenesis of iron/sulfur clusters.
Experimental studies are required to confirm this hypothesis.
In addition, determining the role of nuclear monothiol gluta-
redoxins at their original location will help to understand their
function from an evolutive point of view.
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